Philippe Martin, Chief R&D Officer, expects data for Cenerimod and Selatogrel in late 2026, possibly earlier if enrollment trends continue. CEO Scott Smith plans to return $1-1.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay
Viatris Inc (VTRS) Q4 2024 Earnings Call Highlights: Strong Cash Flow and Debt Reduction Amid ...
